Zevra’s Rene Braeckman, PhD, will present the top-line results from the phase 2 trial evaluating the safety and tolerability of KP1077 for idiopathic hypersomnia at Sleep Europe 2024.
Zevra's new CEO brings 25 years of global biopharmaceutical and life sciences experience.
The company says the name change, a nod to the rare disease community, signifies its commitment to developing treatments for people with rare conditions, including idiopathic hypersomnia.
Read More